The Current State of Traditional Pharmacovigilance

Pharmacovigilance, a cornerstone discipline for ensuring medication safety, is currently facing unprecedented challenges. Manual processing of adverse drug reaction (ADR) reports constitutes a critical bottleneck in the surveillance system.

Underreporting, affecting up to 90% of ADRs, highlights the inherent limitations of the traditional system based on spontaneous reporting. Conventional causality assessment methods—such as the modified Karch-Lasagna algorithm or the Spanish Pharmacovigilance System (SEFV)—although validated and widely used, require manual, case-by-case evaluation. This process, heavily reliant on expert clinical judgment, is being overwhelmed by the increasing volume of generated data, the expanded use of medications, the growth of reporting systems, and the diversification of information sources.

Additional complexity arises from processing unstructured data originating from electronic health records, social media, scientific literature, and global databases. This heterogeneity, combined with reporting biases and the difficulty of detecting late-onset reactions, significantly limits the traditional system’s capacity to identify safety signals in a timely and accurate manner.

The Contribution of Artificial Intelligence to Pharmacovigilance

The integration of artificial intelligence (AI) into pharmacovigilance represents a paradigm shift that directly addresses the fundamental limitations of the traditional model. Machine learning algorithms and natural language processing (NLP) have proven to excel at analyzing large, heterogeneous datasets with a speed and precision that surpass human capabilities.

Automating the processing of individual case safety reports (ICSRs) through AI enables efficient extraction of relevant information from diverse sources. Intelligent systems can automatically code adverse events using the MedDRA terminology, identify duplicates, categorize severity, and assess completeness of reporting forms. This automation significantly reduces the time traditionally required for exhaustive manual review, freeing human resources for higher-value clinical tasks.

AI’s capacity to process unstructured information has considerably expanded the surveillance scope. Analysis of social media, patient forums, and electronic medical records offers valuable insights into real-world patient experiences that often go undetected in formal reporting systems. This active surveillance complements traditional passive methods, providing a more comprehensive view of a drug’s safety profile.

AI systems can continuously scan scientific publications, assess their relevance, and direct critical findings to the appropriate workflows, ensuring that no important safety signal is missed. This continuous monitoring of multiple data sources allows earlier detection of emerging risks and substantially reduces false positives.

The implementation of AI in pharmacovigilance has yielded significant measurable results. Organizations adopting these technologies report a 40–60% reduction in case-processing times, substantial improvements in MedDRA coding accuracy, and greater efficiency in regulatory submissions.

Intelligent case-intake systems can process thousands of ICSR reports simultaneously, automatically classifying them by severity and urgency. In real-world clinical practice, these systems have demonstrated the ability to detect adverse reaction patterns that previously went unnoticed in manual analyses, particularly in specific populations or with complex medications such as biologics.

Ethical and Regulatory Challenges

Deploying AI in pharmacovigilance raises ethical concerns regarding patient privacy and the protection of sensitive data. Systems must strictly comply with regulations such as the EU General Data Protection Regulation (GDPR), the U.S. Health Insurance Portability and Accountability Act (HIPAA), and local data protection laws. It is essential to establish closed data environments where the algorithms and data are both protected and available for regulatory inspection.

AI systems should incorporate enterprise-grade data encryption, granular access controls (fine-grained security measures determining access at a highly specific level), and comprehensive audit trails to support regulatory compliance. Transparency in handling personal data and securing informed patient consent are foundational to the ethical deployment of these technologies.

Rigorous validation of AI algorithms remains one of the most critical challenges. Regulatory agencies require evidence of accuracy, reliability, and consistent risk-signal detection capability. The International Coalition of Medicines Regulatory Authorities (ICMRA) has issued specific recommendations, emphasizing algorithmic transparency and proactive management of AI failure risks.

Systems should include thorough documentation, version control, change tracking, and review capabilities with human oversight. The use of decision-making frameworks such as the RACI matrix (Responsible, Accountable, Consulted, Informed) ensures clear role and responsibility definition within pharmacovigilance teams.

Algorithmic Bias and Mitigation Strategies

Algorithmic bias poses a significant threat to fairness and effectiveness in AI-based pharmacovigilance. Such biases may manifest as demographic bias underrepresenting certain populations, geographic bias favoring data from specific regions, or selection bias in training datasets.

Mitigation strategies include:

Ongoing monitoring of algorithm performance is essential, as AI systems may develop new biases when confronted with previously unseen data.

Precision Medicine in Pharmacovigilance

The convergence of AI and personalized medicine is transforming pharmacovigilance toward a more precise and individualized approach. Intelligent systems can analyze specific genetic profiles, biomarkers, and individual characteristics to predict personalized adverse reactions.

This personalized pharmacovigilance enables:

Precision medicine in pharmacovigilance is especially relevant in genetically diverse populations such as those in Latin America, where genetic variability can lead to differing pharmacological responses.

Benefit–Risk Analysis

AI systems have revolutionized the ongoing assessment of a drug’s benefit–risk profile. Through predictive analytics and machine learning, they can:

This capacity for continuous analysis enables more informed and timely decision-making regarding the safety of marketed medicines.

Future Perspectives and Recommendations

The evolution toward AI-enhanced pharmacovigilance demands an integrated approach combining technological innovation with rigorous ethical and regulatory standards. Key recommendations include:

Multidisciplinary collaboration among programmers, clinicians, regulators, and bioethicists will be essential to harness the full potential of AI in pharmacovigilance. This convergence of expertise will ensure that technological advances serve the primary goal of protecting and improving patient health, setting new standards of excellence in drug safety surveillance.

The future of pharmacovigilance does not lie in replacing human clinical judgment, but in enhancing it through intelligent tools that expand our ability to detect, analyze, and respond to drug risks with unprecedented precision and speed.